Cahn, Avivit https://orcid.org/0000-0002-7830-9994
Mosenzon, Ofri
Wiviott, Stephen D.
Rozenberg, Aliza
Yanuv, Ilan
Goodrich, Erica L.
Murphy, Sabina A.
Bhatt, Deepak L.
Leiter, Lawrence A. https://orcid.org/0000-0002-1040-6229
McGuire, Darren K. https://orcid.org/0000-0002-6412-7989
Wilding, John P.H.
Gause-Nilsson, Ingrid A.M.
Fredriksson, Martin
Johansson, Peter A.
Langkilde, Anna Maria
Sabatine, Marc S.
Raz, Itamar https://orcid.org/0000-0003-0209-4453
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes
https://doi.org/10.1136/dtb.2020.000051
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study (Results)
https://doi.org/10.2337/dc19-1476
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials
https://doi.org/10.1080/13696998.2018.1562817
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
https://doi.org/10.1161/circulationaha.119.044775
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus
https://doi.org/10.1016/j.clinthera.2016.04.037
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
https://doi.org/10.1161/circulationaha.121.058103
Transforming the Care of Patients with Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18641120
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Nonglycemic Outcomes of Antidiabetic Medications
https://doi.org/10.2337/cd18-0015
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58 (Results)
https://doi.org/10.2337/dc20-2492
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
https://doi.org/10.2337/dc21-0076
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6